Sep 2026· European journal of medicinal chemistry· Vol 320, pp.
119307
· 0 citations· 92 references
Medicine
TL;DR
This review covers 2020-2026 advances in CA-targeted drug discovery: high-resolution CA structures; allosteric regulation by host metabolite IP6; medicinal chemistry optimization of PF74 derivatives via scaffold hopping and conformational restriction to enhance potency and metabolic stability; the development and clinical use of lenacapavir-the first ultra-long-acting CA inhibitor-and mechanisms of resistance.
Abstract
HIV-1 capsid (CA) protein is a key target for next-generation antiretrovirals, driving multiple stages of the viral life cycle. This review covers 2020-2026 advances in CA-targeted drug discovery: high-resolution CA structures; allosteric regulation by host metabolite IP6; medicinal chemistry optimization of PF74 derivatives via scaffold hopping and conformational restriction to enhance potency and metabolic stability; the development and clinical use of lenacapavir-the first ultra-long-acting CA inhibitor-and mechanisms of resistance (e.g., M66I); emerging inhibitors against resistant strains and cryptic binding sites; and current challenges. We also briefly discuss emerging approaches such as AI-driven design and PROTACs (Proteolysis-Targeting Chimeras), and highlight long-acting combination regimens as a promising path toward an HIV-1 functional cure.
Herpes simplex virus type 1 (HSV-1) causes widespread human infection, for which curative therapies remain unavailable. First-line TK-dependent nucleoside analogues such as acyclovir fail to eradicate latent virus and show limited activity against drug-resistant variants, highlighting an urgent unmet medical need. This...
Qiao-Mei Zhou, Bao-Hu Li, Ye-Hong Dai et al.· European journal of medicina...· 0 citations
Human Immunodeficiency Virus type 1 (HIV-1) integrase is an essential enzyme that inserts viral DNA into human host cell genomes. Rising clinical resistance to established integrase strand transfer inhibitors (INSTIs) necessitates novel therapeutic strategies. Here, we designed ten de novo small-molecule inhibitors (NI...
P. Muthenna· International journal of all...· 0 citations
This review highlights promising protein-based HIV entry inhibitors that have demonstrated efficacy in preclinical studies, and discusses ongoing efforts to optimize their valency, avidity, specificity, serum half-life, effector functions, and production platforms to improve their therapeutic potential and economic fea...
Rashmi Kumariya, Carole A. Bewley· Biomolecules· 0 citations
Drug resistance remains a major hurdle in antiviral drug development. This review highlights the “substrate envelope hypothesis”, a structure-based drug design (SBDD) paradigm that constrains the spatial boundaries and binding footprint of inhibitors within the conserved active site volume defined by natural viral subs...
Peptide-based fusion inhibitors are promising pharmaceuticals in the fight against enveloped viruses relying on membrane fusion for host infection. However, peptide therapeutic applications have long been hindered by their poor stability in vivo. Here, we discovered that peptide inhibitors with the wildtype sequence of...
Kailu Yang, Chu-Chu Wang, Francesco Topi et al.· bioRxiv· 0 citations
Given its pivotal role in the viral life cycle, blocking integrase (IN) through IN strand transfer inhibitors (INSTIs) represented a breakthrough in the treatment of HIV infection, establishing these antiretroviral regimens as first‐line options against AIDS. However, the onset of drug‐resistant strains has challenged...
Francesco Saccoliti, E. Patacchini, Emanuele Cara et al.· ChemMedChem· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
